Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters – A Non-Invasive, Safe, and Effective Therapeutic Option
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
On this episode of the JVRD Author’s Forum podcast, vitreoretinal specialists Drs. Jeanette Du and Mohsin Ali of the Retina Group of Washington discuss their study, “Low-Dose Atropine Drops for Symptomatic Vitreous Floaters: A Non-invasive, Safe, and Effective Therapeutic Option,” published in the November/December 2025 issue of JVRD.
Host Dr. Timothy Murray speaks with Drs. Du and Ali discuss how their clinical experiences treating patients with persistent, symptomatic floaters led them to explore low-dose atropine as a conservative alternative to more invasive options such as vitrectomy or YAG vitreolysis.
Their research shows that 0.01% atropine may help reduce the perception of floaters for a meaningful subset of patients, offering a safe, non-invasive option that can be used long-term or as a temporizing measure before considering procedural treatment.
For more information, visit www.ASRS.org/JVRDForum.
Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief of JVRD, as he discusses cutting-edge developments featured in JVRD with the lead authors, who share clinical pearls and explore their significance in advancing patient care.